Lee Mihwa, Chan Camilla W, Graham Stephen C, Christopherson Richard I, Guss J Mitchell, Maher Megan J
School of Molecular and Microbial Biosciences, University of Sydney, New South Wales 2006, Australia.
J Mol Biol. 2007 Jul 27;370(5):812-25. doi: 10.1016/j.jmb.2007.05.019. Epub 2007 May 22.
Dihydroorotase (DHOase) catalyzes the reversible cyclization of N-carbamyl-L-aspartate (CA-asp) to L-dihydroorotate (DHO) in the de novo biosynthesis of pyrimidine nucleotides. DHOase is a potential anti-malarial drug target as malarial parasites can only synthesize pyrimidines via the de novo pathway and do not possess a salvage pathway. Here we report the structures of Escherichia coli DHOase crystallized without ligand (1.7 A resolution) and in the presence of the inhibitors 2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylate (HDDP; 2.0 A) and 5-fluoroorotate (FOA, 2.2 A). These are the first crystal structures of DHOase-inhibitor complexes, providing structural information on the mode of inhibitor binding. HDDP possesses features of both the substrate and product, and ligates the Zn atoms in the active site. In addition, HDDP forms hydrogen bonds to the flexible loop (residues 105-115) stabilizing the "loop-in" conformation of the flexible loop normally associated with the presence of CA-asp in the active site. By contrast, FOA, a product-like inhibitor, binds to the active site in a similar fashion to DHO but does not ligate the Zn atoms directly nor stabilize the loop-in conformation. These structures define the necessary features for the future design of improved inhibitors of DHOase.
二氢乳清酸酶(DHOase)在嘧啶核苷酸的从头生物合成过程中催化N-氨甲酰-L-天冬氨酸(CA-asp)可逆环化生成L-二氢乳清酸(DHO)。DHOase是一种潜在的抗疟药物靶点,因为疟原虫只能通过从头途径合成嘧啶,而不具备补救途径。在此,我们报道了未结合配体(分辨率为1.7 Å)以及结合抑制剂2-氧代-1,2,3,6-四氢嘧啶-4,6-二羧酸(HDDP;分辨率为2.0 Å)和5-氟乳清酸(FOA,分辨率为2.2 Å)时大肠杆菌DHOase的晶体结构。这些是DHOase-抑制剂复合物的首批晶体结构,提供了关于抑制剂结合模式的结构信息。HDDP兼具底物和产物的特征,并与活性位点中的锌原子结合。此外,HDDP与柔性环(残基105 - 115)形成氢键,稳定了通常与活性位点中CA-asp存在相关的柔性环的“环内”构象。相比之下,FOA是一种类似产物的抑制剂,它以与DHO相似的方式结合到活性位点,但不直接与锌原子结合,也不稳定环内构象。这些结构确定了未来设计更优DHOase抑制剂的必要特征。